TY - JOUR
T1 - Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration
AU - Linde, Louise
AU - Ørnbjerg, Lykke M
AU - Rasmussen, Simon H
AU - Love, Thorvardur Jon
AU - Loft, Anne Gitte
AU - Závada, Jakub
AU - Vencovský, Jiří
AU - Laas, Karin
AU - Nordstrom, Dan
AU - Sokka-Isler, Tuulikki
AU - Gudbjornsson, Bjorn
AU - Gröndal, Gerdur
AU - Iannone, Florenzo
AU - Ramonda, Roberta
AU - Hellamand, Pasoon
AU - Kristianslund, Eirik K
AU - Kvien, Tore K
AU - Rodrigues, Ana M
AU - Santos, Maria J
AU - Codreanu, Catalin
AU - Rotar, Ziga
AU - Tomšič, Matija
AU - Castrejon, Isabel
AU - Díaz-Gonzáles, Federico
AU - Di Giuseppe, Daniela
AU - Ljung, Lotta
AU - Nissen, Michael J
AU - Ciurea, Adrian
AU - Macfarlane, Gary J
AU - Heddle, Maureen
AU - Glintborg, Bente
AU - Østergaard, Mikkel
AU - Hetland, Merete L
N1 - COPECARE
© 2023. BioMed Central Ltd., part of Springer Nature.
PY - 2023/10/19
Y1 - 2023/10/19
N2 - BACKGROUND: In European axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) clinical registries, we aimed to investigate commonalities and differences in (1) set-up, clinical data collection; (2) data availability and completeness; and (3) wording, recall period, and scale used for selected patient-reported outcome measures (PROMs).METHODS: Data was obtained as part of the EuroSpA Research Collaboration Network and consisted of (1) an online survey and follow-up interview, (2) upload of real-world data, and (3) selected PROMs included in the online survey.RESULTS: Fifteen registries participated, contributing 33,948 patients (axSpA: 21,330 (63%), PsA: 12,618 (37%)). The reported coverage of eligible patients ranged from 0.5 to 100%. Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-reactive protein was available in all registries with data completeness between 85% and 100%. All PROMs (Bath Ankylosing Spondylitis Disease Activity and Functional Indices, Health Assessment Questionnaire, and patient global, pain and fatigue assessments) were more complete after 2015 (68-86%) compared to prior (50-79%). Patient global, pain and fatigue assessments showed heterogeneity between registries in terms of wording, recall periods, and scale.CONCLUSION: Important heterogeneity in registry design and data collection across fifteen European axSpA and PsA registries was observed. Several core measures were widely available, and an increase in data completeness of PROMs in recent years was identified. This study might serve as a basis for examining how differences in data collection across registries may impact the results of collaborative research in the future.
AB - BACKGROUND: In European axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) clinical registries, we aimed to investigate commonalities and differences in (1) set-up, clinical data collection; (2) data availability and completeness; and (3) wording, recall period, and scale used for selected patient-reported outcome measures (PROMs).METHODS: Data was obtained as part of the EuroSpA Research Collaboration Network and consisted of (1) an online survey and follow-up interview, (2) upload of real-world data, and (3) selected PROMs included in the online survey.RESULTS: Fifteen registries participated, contributing 33,948 patients (axSpA: 21,330 (63%), PsA: 12,618 (37%)). The reported coverage of eligible patients ranged from 0.5 to 100%. Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-reactive protein was available in all registries with data completeness between 85% and 100%. All PROMs (Bath Ankylosing Spondylitis Disease Activity and Functional Indices, Health Assessment Questionnaire, and patient global, pain and fatigue assessments) were more complete after 2015 (68-86%) compared to prior (50-79%). Patient global, pain and fatigue assessments showed heterogeneity between registries in terms of wording, recall periods, and scale.CONCLUSION: Important heterogeneity in registry design and data collection across fifteen European axSpA and PsA registries was observed. Several core measures were widely available, and an increase in data completeness of PROMs in recent years was identified. This study might serve as a basis for examining how differences in data collection across registries may impact the results of collaborative research in the future.
UR - http://www.scopus.com/inward/record.url?scp=85174463114&partnerID=8YFLogxK
U2 - 10.1186/s13075-023-03184-7
DO - 10.1186/s13075-023-03184-7
M3 - Journal article
C2 - 37858143
SN - 1478-6354
VL - 25
JO - Arthritis Research & Therapy
JF - Arthritis Research & Therapy
IS - 1
M1 - 205
ER -